Home
News
Create
Screeners
Insights
Rubicon Research
678.
95
-5.30
(-0.77%)
Market Cap
₹11,185.72 Cr
PE Ratio
83.72
Industry
Healthcare
Buy
Sell
Company Performance:
1D
-0.77%
1M
+2.45%
6M
+8.08%
1Y
+8.08%
5Y
+8.08%
View Company Insights
Latest news about Rubicon Research
Rubicon Research Limited Reports GST Inspection at Thane and Ambernath Offices
2 days ago
Rubicon Research Limited reported that GST authorities initiated inspection proceedings at its Thane and Ambernath offices on January 30, 2026, under Section 67 of the Maharashtra GST Act. The company is providing full cooperation to officials while business operations continue normally. Based on initial assessment, no material impact on financials or operations is expected from these proceedings.
Rubicon Research Limited Schedules Board Meeting on February 3, 2026 for Q3FY26 Financial Results
5 days ago
Investec Initiates Buy Rating on Rubicon Research with ₹820 Target Price, Projects 47% EPS CAGR
Jan 13, 2026
Rubicon Research Limited Appoints Ms. Avani Harish Shah as General Manager for Legal and Compliance
Jan 09, 2026
Rubicon Research Subsidiary AdvaGen Pharma Receives ₹4.19 Crore Tax Demand Notice
Jan 06, 2026
More news about Rubicon Research
08
Dec 25
Rubicon Research Limited Shareholders Approve All Six Resolutions in Postal Ballot
Rubicon Research, a pharmaceutical company, announced that its shareholders have approved all six resolutions proposed in a recent postal ballot. The voting, which concluded on December 7, 2025, was conducted through remote e-voting. Shareholder support ranged from 88.81% to 95.18% in favor of the resolutions. The approved resolutions included a promoter agreement and ratification of employee stock option plans. This strong support indicates confidence in the company's management and strategic direction.
13
Nov 25
Rubicon Research Reports Strong Q2 Growth with 56% Jump in Net Profit
Rubicon Research Limited posted strong Q2 FY2026 results with net profit up 56.2% to 539 million rupees and revenue rising 39.2% to 4.12 billion rupees. EBITDA grew 52.9% to 943 million rupees with margin improving to 22.9%. The company's product diversification strategy showed progress with top 5 products now contributing 30% of revenue, down from 34% in Q1. R&D expenses were 11.2% of operating revenue at 475.89 million rupees. Rubicon plans to operationalize its Pithampur plant in mid-2026 to address capacity constraints. The company maintains a strong financial position with 1,514 million rupees in cash and cash equivalents.
13
Nov 25
Rubicon Research Reports Insider Trading Violations, Issues Warnings
Rubicon Research Limited disclosed two cases of insider trading violations. The first involved VP Amol Shamrao Masal selling 30 shares on October 28, 2025, violating contra trade rules and trading window closure. The second case involved HR Head Romola Pinto and relative Vikram N Pinto acquiring 20 shares on October 16, 2025, during a closed trading window. Both trades were deemed inadvertent and of insignificant amounts. The company issued warning letters to the parties involved and reported the incidents to stock exchanges in compliance with SEBI regulations.
Rubicon Research
678.
95
-
5.
30
(-
0.
77
%)
1 Year Returns:
+8.08%
Industry Peers
Sun Pharmaceutical
1,610.10
(+
0.
93
%)
Divis Laboratories
6,056.00
(+
0.
08
%)
Torrent Pharmaceuticals
3,997.10
(+
0.
92
%)
Cipla
1,328.90
(+
0.
37
%)
Dr Reddys Laboratories
1,178.70
(-
3.
23
%)
Lupin
2,135.20
(-
0.
82
%)
Zydus Life Science
878.10
(-
0.
81
%)
Mankind Pharma
2,093.90
(-
1.
42
%)
Aurobindo Pharma
1,172.10
(-
2.
95
%)
Alkem Laboratories
5,565.00
(-
1.
98
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/Block Deals
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation